Comparative safety of bone remodeling agents with a focus on osteoporosis therapies

被引：12
作者：
Kleerekoper, M
Schein, JR
机构：
[1] Wayne State Univ, Sch Med, Dept Internal Med, Div Endocrinol, Detroit, MI 48201 USA
[2] Novartis Pharmaceut Corp, E Hanover, NJ USA
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 2001年 / 41卷 / 03期
关键词：
D O I：
10.1177/00912700122010050
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
This article reviews the different treatments currently available for osteoporosis and examines the benefits and adverse events that are associated with each. While emphasizing safety considerations, this review summarizes the following treatments for osteoporosis: calcium supplements, fluoride, hormone replacement therapy, raloxifene, bisphosphonates, salmon calcitonin, and calcitriol. Before prescribing any of these agents, the clinician should review the risk/benefit profile of each drug in the context of the individual patient's history, concomitant diseases, concurrent medications, and general physical condition. Journal of Clinical Pharmacology, 2001;41:239-250 (C) 2001 the American College of Clinical Pharmacalogy.
引用
收藏
页码：239 / 250
页数：12
相关论文
共 106 条
[1]   THE ACUTE-PHASE RESPONSE AFTER BISPHOSPHONATE ADMINISTRATION [J].
ADAMI, S ;
BHALLA, AK ;
DORIZZI, R ;
MONTESANTI, F ;
ROSINI, S ;
SALVAGNO, G ;
LOCASCIO, V .
CALCIFIED TISSUE INTERNATIONAL, 1987, 41 (06) :326-331
[2]  
Ashworth LE, 1998, FORMULARY, V33, P305
[3]  
*AV PHARM, 2000, ACTONEL MAN PRESCR I
[4]   THE EFFECTS OF 2-YEAR TREATMENT WITH THE AMINOBISPHOSPHONATE ALENDRONATE ON BONE METABOLISM, BONE HISTOMORPHOMETRY, AND BONE STRENGTH IN OVARIECTOMIZED NONHUMAN-PRIMATES [J].
BALENA, R ;
TOOLAN, BC ;
SHEA, M ;
MARKATOS, A ;
MYERS, ER ;
LEE, SC ;
OPAS, EE ;
SEEDOR, JG ;
KLEIN, H ;
FRANKENFIELD, D ;
QUARTUCCIO, H ;
FIORAVANTI, C ;
CLAIR, J ;
BROWN, E ;
HAYES, WC ;
RODAN, GA .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (06) :2577-2586
[5]   Differential response of estrogen receptor α and estrogen receptor β to partial estrogen agonists/antagonists [J].
Barkhem, T ;
Carlsson, B ;
Nilsson, Y ;
Enmark, E ;
Gustafsson, JÅ ;
Nilsson, S .
MOLECULAR PHARMACOLOGY, 1998, 54 (01) :105-112
[6]  
Baudoin C, 1997, REV RHUM, V64, P441
[7]   Etidronate and alendronate in the treatment of postmenopausal osteoporosis [J].
Beauchesne, MF ;
Miller, PF .
ANNALS OF PHARMACOTHERAPY, 1999, 33 (05) :587-599
[8]  
Beral V, 1997, LANCET, V349, P1103, DOI 10.1016/S0140-6736(05)62328-8
[9]   Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women [J].
Beresford, SAA ;
Weiss, NS ;
Voigt, LF ;
McKnight, B .
LANCET, 1997, 349 (9050) :458-461
[10]   Nonclinical model for assessing gastric effects of bisphosphonates [J].
Blank, MA ;
Ems, BL ;
Gibson, GW ;
Myers, WR ;
Berman, SK ;
Phipps, RJ ;
Smith, PN .
DIGESTIVE DISEASES AND SCIENCES, 1997, 42 (02) :281-288
12345678910